Publication Date
2-1-2025
Journal
Otolaryngology–Head and Neck Surgery
DOI
10.1002/ohn.1079
PMID
39666828
PMCID
PMC11773442
PubMedCentral® Posted Date
12-12-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, Infant, Newborn, Neonatal Screening, Cytomegalovirus Infections, United States, Cochlear Implants, Cochlear Implantation, Societies, Medical, congenital cytomegalovirus, hearing loss, newborn screening
Abstract
It is estimated that 1 in every 200 US newborns has congenital cytomegalovirus (cCMV). Delayed identification of cCMV in newborns precludes timely intervention to mitigate sequelae of the infection such as hearing loss and other neurological complications. Newborn testing for cCMV enables appropriate diagnosis and intervention by multidisciplinary teams to properly manage the immediate sequelae of cCMV, avoid unnecessary additional testing that can result from delayed diagnosis, and monitor for future complications. It is the position of the American Cochlear Implant Alliance, the National CMV Foundation, and the American Academy of Otolaryngology-Head and Neck Surgery that universal newborn cCMV screening is necessary to best accomplish these goals.
Included in
Medical Sciences Commons, Mental and Social Health Commons, Otolaryngology Commons, Otorhinolaryngologic Diseases Commons, Pediatrics Commons, Surgery Commons
